Clinical trial
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in…
NCT00458237 · Beth Israel Deaconess Medical Center, Other · Completed
Key facts
| NCT number | NCT00458237 |
|---|---|
| Title | Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer |
| Official title | A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Everolimus, Trastuzumab |
| Enrollment | 11 |
| Start date | Apr 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Apr 10, 2007 |
| Last update posted | Oct 20, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: